Photo from wikipedia
Key Points Question Is neoadjuvant endocrine therapy (NET) an alternative treatment for neoadjuvant chemotherapy (NACT) in patients with invasive ductal carcinoma (IDC) of the breast who have strong hormone receptor… Click to show full abstract
Key Points Question Is neoadjuvant endocrine therapy (NET) an alternative treatment for neoadjuvant chemotherapy (NACT) in patients with invasive ductal carcinoma (IDC) of the breast who have strong hormone receptor (HR) positivity and human epidermal growth factor receptor 2 (ERBB2) negativity? Findings This cohort study of 640 patients undergoing NET or NACT found that the adjusted hazard ratios for all-cause mortality in the NET group were significantly higher than in the NACT group. Meaning These findings suggest that NACT may be considered the first choice for neoadjuvant treatment for patients with strongly HR-positive and ERBB2-negative IDC.
Journal Title: JAMA Network Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!